Efficacité et tolérance de l'insuline dégludec dans le diabète de type 1 et de type 2 : résultats des essais cliniques de phase IIIa

Insulin degludec has a flat and stable profile at steady state, with less within-subject variability in glucose lowering activity from day to day. Long-acting insulin degludec has been studied in a large-scale clinical phase 3a trial program, examining its impact on glucose control, safety, hypoglycemia and the possibility to flexibly adjust insulin degludec dosing time to suit patient needs. More than 5,000 patients with type 1 or type 2 diabetes were enrolled.